An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals
- PMID: 20122669
- DOI: 10.1016/j.nucmedbio.2009.09.001
An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals
Abstract
Introduction: Stable attachment of (64)Cu(2+) to a targeting molecule usually requires the use of a bifunctional chelator (BFC). Sarcophagine (Sar) ligands rapidly coordinate (64)Cu(2+) within the multiple macrocyclic rings comprising the cage structure under mild conditions, providing high stability in vivo. Previously, we have designed a new versatile cage-like BFC Sar ligand, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid (AmBaSar), for (64)Cu radiopharmaceuticals. Here we report the improved synthesis of AmBaSar, (64)Cu(2+) labeling conditions and its biological evaluation compared with the known BFC 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA).
Methods: The AmBaSar was synthesized in four steps starting from (1,8-diamine-Sar) cobalt(III) pentachloride ([Co(DiAmSar)]Cl(5)) using an improved synthetic method. The AmBaSar was labeled with (64)Cu(2+) in pH 5.0 ammonium acetate buffer solution at room temperature, followed by analysis and purification with HPLC. The in vitro stability of (64)Cu-AmBaSar complex was evaluated in phosphate buffered saline (PBS), fetal bovine serum and mouse blood. The microPET imaging and biodistribution studies of (64)Cu-AmBaSar were performed in Balb/c mice, and the results were compared with (64)Cu-DOTA.
Results: The AmBaSar was readily prepared and characterized by MS and (1)H NMR. The radiochemical yield of (64)Cu-AmBaSar was >or=98% after 30 min of incubation at 25 degrees C. The (64)Cu-AmBaSar complex was analyzed and purified by HPLC with a retention time of 17.9 min. The radiochemical purity of (64)Cu-AmBaSar was more than 97% after 26 h of incubation in PBS or serum. The biological evaluation of (64)Cu-AmBaSar in normal mouse demonstrated renal clearance as the primary mode of excretion, with improved stability in vivo compared to (64)Cu-DOTA.
Conclusions: The new cage-like BFC AmBaSar was prepared using a simplified synthetic method. The (64)Cu-AmBaSar complex could be obtained rapidly with high radiochemical yield (>/=98%) under mild conditions. In vitro and in vivo evaluation of AmBaSar demonstrated its promising potential for preparation of (64)Cu radiopharmaceuticals.
Copyright 2010. Published by Elsevier Inc.
Similar articles
-
Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression.Bioconjug Chem. 2010 Aug 18;21(8):1417-24. doi: 10.1021/bc900537f. Bioconjug Chem. 2010. PMID: 20666401
-
Synthesis of a novel bifunctional chelator AmBaSar based on sarcophagine for peptide conjugation and (64)Cu radiolabelling.Dalton Trans. 2009 Jul 21;(27):5395-400. doi: 10.1039/b902210d. Epub 2009 May 22. Dalton Trans. 2009. PMID: 19565091
-
64Cu-Labeled 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo [6.6.6] icosane-1-ylamino)methyl)benzoic acid (AmBaSar).2010 Sep 23 [updated 2010 Oct 28]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2010 Sep 23 [updated 2010 Oct 28]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 21061497 Free Books & Documents. Review.
-
(64)Cu labeled AmBaSar-RGD2 for micro-PET imaging of integrin αvβ3 expression.Curr Radiopharm. 2011 Jan;4(1):68-74. doi: 10.2174/1874471011104010068. Curr Radiopharm. 2011. PMID: 22191616
-
64Cu-Labeled 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo [6.6.6] icosane-1-ylamino)methyl)benzoic acid (AmBaSar) conjugated to cyclic arginine-glycine-aspartic acid (RGD) peptide.2010 Sep 20 [updated 2010 Oct 28]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2010 Sep 20 [updated 2010 Oct 28]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 21061495 Free Books & Documents. Review.
Cited by
-
Efficient construction of PET/fluorescence probe based on sarcophagine cage: an opportunity to integrate diagnosis with treatment.Mol Imaging Biol. 2012 Dec;14(6):718-24. doi: 10.1007/s11307-012-0557-z. Mol Imaging Biol. 2012. PMID: 22476968
-
Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs.Biomaterials. 2013 Apr;34(12):3098-109. doi: 10.1016/j.biomaterials.2013.01.039. Epub 2013 Jan 30. Biomaterials. 2013. PMID: 23375392 Free PMC article.
-
The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.Molecules. 2022 May 10;27(10):3062. doi: 10.3390/molecules27103062. Molecules. 2022. PMID: 35630536 Free PMC article. Review.
-
Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications.Cancer Imaging. 2024 Sep 20;24(1):127. doi: 10.1186/s40644-024-00762-z. Cancer Imaging. 2024. PMID: 39304961 Free PMC article. Review.
-
(64)Cu labeled sarcophagine exendin-4 for microPET imaging of glucagon like peptide-1 receptor expression.Theranostics. 2014 May 24;4(8):770-7. doi: 10.7150/thno.7759. eCollection 2014. Theranostics. 2014. PMID: 24955138 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous